drugset / Trial / NCT06766864
A Study of Subcutaneous DR-01 in Healthy Volunteers
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, and PD of SC administration of single ascending doses of DR-01 in healthy volunteers.
Timeline
- Start
- 2025-03-03
- Primary completion
- 2025-08-27
- Completion
- 2025-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dibotatug | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.